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Abstract
Introduction: One major challenge in personalized medicine research is to identify the environmental factors that
can alter drug response, and to investigate their molecular mechanisms. These environmental factors include
co-medications, food, and nutrition or dietary supplements. The increasing use of dietary supplements and their
potential interactions with cytochrome P450 (CYP450) enzymes is a highly significant personalized medicine
research domain, because most of the drugs on the market are metabolized through CYP450 enzymes.
Methods: Initial bioinformatics analysis revealed a number of regulators of CYP450 enzymes from a human liver
bank gene expression quantitative loci data set. Then, a compound-gene network was constructed from the
curated literature data. This network consisted of compounds that interact with either CYPs and/or their regulators
that influence either their gene expression or activity. We further evaluated this finding in three different cell lines:
JEG3, HeLa, and LNCaP cells.
Results: From a total of 868 interactions we were able to identify an interesting interaction between retinoic acid
(i.e. Vitamin A) and the aromatase gene (i.e. CYP19A1). Our experimental results showed that retinoic acid at
physiological concentration significantly influenced CYP19A1 gene expressions.
Conclusions: These results suggest that the presence of retinoic acid may alter the efficacy of agents used to
suppress aromatase expression.
Introduction
The Cytochrome P450 system consists of 57 enzymes,
which are further classified into 18 families and 43 subfa-
milies based on sequence similarity [1]. They play a crucial
role in the metabolism of various chemicals both endogen-
ous and exogenous [2]. The members of the first three
CYP families 1-3 are mainly involved in the metabolism of
exogenous compounds such as medications, whereas the
members of the other families are involved largely in the
metabolism of endogenous compounds such as choles-
terol, bile acids, steroid hormones and fatty acids. A given
CYP enzyme can metabolize multiple substrates and a
given substrate can be metabolized by multiple CYPs.
Mutations or the absence of genes encoding the CYP
enzymes can not only result in altered drug response but
can also make an individual more susceptible to human
disease such as glaucoma [3-7] and elevated cholesterol
[8].Even a single mutation has the potential to alter the
structure of these enzymes, resulting in altered activity or
substrate specificity [9]. Furthermore, the co-administra-
tion of multiple drugs can influence the enzymes involved
in their metabolism either through induction or inhibition
[10]. Age and sex as well can influence CYP activity,
studies have shown that CYP3A4 activity is higher in adults
compared to fetus [11] and that women metabolize
CYP3A4 faster than men [12,13]. A wealth of information
on the CYP variants is available at the Human Cytochrome
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P450 Allele Nomenclature website [14]. Despite the pre-
sence of this large amount of information it is still challen-
ging to optimize therapy to meet an individual’s needs,
especially with the increasing usage of supplements and
herbal medications.
One of the challenges of personalized medicine is to
identify or fine tune drug combinations without drastically
affecting the metabolic pathway of either. There are
numerous studies that have shown that the activity of
these enzymes are influenced by various upstream regula-
tory mechanisms [13,15-24], which in turn can potentially
influence drug response. Despite the use of various patient
characteristics there still exist a substantial amount of
variations in drug response and mainly due to the nature
and combinations of sources of variation. One such factor
is the increasing use of dietary supplements that are not
always taken into account while drugs are prescribed,
which can potentially alter Cytochrome P450 activity
[25,26]. The mining of previously published literature
across various disciplines has been very useful and effective
in identifying potential drug interaction and rofecoxib is an
excellent example, where the drugs toxic effect was present
in literature before the drug was recalled [27]. Thus trans-
lational bioinformatics methods summarizing the literature
data have proven to be an effective way of uncovering
interactions that could be beneficial or harmful. In our
study we were able to identify a correlation between reti-
noic acid and aromatase gene expression through bioinfor-
matics analyses of existing databases. We were able to
functionally validate this bioinformatic prediction in three
different cell lines using physiological concentrations of
retinoic acid. Our studies show that retinoic acid substan-
tially alters the expression of the aromatase gene.
Methods
CYPs and their super-regulators
For this study we choose seven CYP subfamilies (CYP1A,
CYP2A, CYP2B, CYP2C, CYP2D, CYP2E, and CYP3A)
that are mainly responsible for metabolizing more than
90% of drugs as well as CYP19A1 that is largely involved
in the biosynthesis of estrogens. In order to identify com-
pounds that indirectly affected the CYP activity/expression
we used previously published endogenous CYP regulators
[13,15-24] from the literature and those that had a signifi-
cant influence over the expression as well as activity of
these CYP enzymes from the human liver bank gene
expression quantitative loci data set [28]. These endogen-
ous CYP regulators that had a direct effect on CYP
enzymes were used as seed to identify compounds (Super-
Regulators) that in turn influenced their regulation.
Identification of compounds that influence CYP regulators
The endogenous CYP regulators were uploaded into
Metacore (Thomson Reuters, NY, USA), a web based
computational tool backed by text mining capabilities to
build a highly interconnected network of CYP regulators
and compounds that influenced their expression. Each
node in the network represented a CYP regulator or a
compound and the edges represented the interaction
between the two denoting either an activation or inhibi-
tion. Not all CYP regulators were associated with
upstream compounds. The CYP regulators that were
not associated with any compounds and compounds
that had fewer than 3 edges were eliminated from
further analysis. The CYP regulators from the above list
(compounds (edges =>3) - CYP regulator) were used to
build a second network along with the 10 CYP enzymes,
namely CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8,
CYP2C9, CYP2D6, CYP2E1,CYP3A4, AND CYP19A1 to
further confirm the interactions between them. The
results from the above two networks namely the [Com-
pounds (edges =>3) - CYP regulator] and [CYP regula-
tor- CYP enzyme] was merged to form the final
network using Cytoscape [29] to represent the overall
interaction between the compounds, CYP regulators and
CYP enzymes. Using this network the path from a given
compound to its terminal leaf, which was either a CYP
regulator or CYP enzyme was traced, thus predicting
the interaction between the compound and CYPs.
Influence of retinoic acid on DAX1/CYP19A1 gene
expression
Cell culture and treatment
Three cell lines namely, JEG3 (Placental Cancer), HeLa
(Cervical Cancer), and LNCAP (Prostate Cancer) were
chosen to study the expression of the CYP19A1 (Aroma-
tase) and DAX1 genes. The cells were plated in six T25
flasks at a density of 0.25 × 106 cells/ flask and grown in
DMEM with 10% FBS. After 24 hours the media was
removed and the cells were washed 3 times with DMEM
containing 10% charcoal stripped FBS and cells were then
allowed to grow in the new media. The media was
replaced with fresh media every 24 hours for two more
days. After 72 hours of initial media change the cells in
each of the six flasks were treated with either vehicle
(0.01% Ethanol) or All Trans Retinoic Acid (ATRA)
(Sigma-Aldrich, USA) at 0.1nM. 1nM, 10nM, 100nM and
1000nM respectively.
RNA extraction, cDNA synthesis and gene expression
After 24 hours of treatment the cells were harvested and
RNA extracted using miRNeasy Kit (Qiagen Inc., USA)
according to the manufactures protocol. The RNA was
then quantified using Quant-IT Kit (Life Technologies,
USA) on the Qubit Fluorometer (Life Technologies, USA)
according to the manufactures protocol. The cDNA was
synthesized using the QuantiTect Reverse Transcription
Kit (Qiagen Inc. USA) according to the manufactures
Philips et al. BMC Genomics 2015, 16(Suppl 7):S17
http://www.biomedcentral.com/1471-2164/16/S7/s17
Page 2 of 7
protocol from 1ug of RNA. The gene expression for
CYP19A1 and DAX1 was measured with the respective
Taqman Gene Expression Assays (Life Technologies,
USA) on the iCycler instrument (Bio-Rad Inc., USA) in
accordance with the manufactures protocol.
Results
CYPs and their regulatory network
The initial network between the compounds and CYP reg-
ulators consisted of 868 edges between the compounds
and CYP regulators, with 15 large clusters (Figure 1). The
top 15 clusters were around the following CYP regulators
namely, ESR1, PXR, PPARalpha, LXRalpha, GCRalpha,
LXRbeta, AHR, PPARgamma, PPARbeta, VDR, FXR,
RXRbeta, LHR, CAR and TRbeta. The number of com-
pounds that formed these cluster ranged from 187 to 7,
thus representing the extent to which a single CYP regula-
tor can be influenced by multiple compounds. This net-
work was further reduced by eliminating compounds that
had less than 3 edges with other CYP regulators. The final
Figure 1 Compound - CYP Regulator Network. The above figure depicts the overall network consisting of 868 interaction between the
various compounds and CYP regulators that they affect. The density of the cluster is proportional to the number of compounds that influence
its activity, and the nodes between clusters represents the compounds that influence more than one CYP regulator. The top 15 clusters were
formed around ESR1, PXR, PPARalpha, LXRalpha, GCRalpha, LXRbeta, AHR, PPARgamma, PPARbeta, VDR, FXR, RXRbeta, LHR, CAR and TRbeta (the
respective nodes are highlighted in red and interaction between retinoic acid and DAX1 is highlighted by the yellow rectangle).
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regulatory network mainly consisted of the 134 edges
between 42 nodes which included 9 CYPs, 16 CYP regula-
tors and 17 compounds (Figure 2). All of the drug meta-
bolizing CYP enzymes including the CYP19A1 had either
a compound or CYP regulator upstream. Only CYP2E1
did not have any compound or CYP regulators associated
with it. The resultant network clearly indicated the poten-
tial influence of retinoic acid (Vitamin A) on the expres-
sion of CYP19A1 (Aromatase) through DAX1.
Influence of ATRA on CYP19A1 (Aromatase) and DAX1
genes in the various cell lines
The above hypothesis that retinoic acid alters the
expression of aromatase gene was experimentally veri-
fied using three different cells lines, namely JEG3, HeLa
and LNCaP. Each cell line was treated with various con-
centrations of ATRA ranging from 0.1nM to 1uM,
which included the physiological concentration at which
retinoic acid is found in humans. The physiological con-
centration of retinoic acid in human plasma is around
4.9 ng/ml and all-trans retinoic acid (ATRA) accounts
for ~75% of the total [30]. After a 24 hour treatment
period the cells were harvested, RNA extracted and the
expression was measured for CYP19A1 and DAX1 using
the respective Taqman gene expression assays. The
expression of aromatase gene increased proportionally
with increasing concentrations of ATRA and tapered off
at 10nM ATRA (Table 1, Figure 3). DAX1 expression
was observed only in the HeLa cell line showing a
decrease in activity with increasing concentration of
ATRA (Figure 4). The above experiments were per-
formed in triplicates on different days for each cell line.
A one-way between treatments ANOVA was con-
ducted to compare the effect of retinoic acid on the
expression of CYP19A1 and DAX1 in the three different
cell lines. There was a significant effect of retinoic acid
on the expression of CYP19A1 and DAX1 at the P <
0.05 level in the HeLa cell line (Table 1). Further, post
hoc comparison using the Tukey test showed that the
fold change for treatments (0.1nM, 1nM, 10nM and
100nM) were significantly different from treatment at
1000nM. Thus indicating that the expression of aroma-
tase gene proportionally increased with an increasing
concentration of retinoic acid reaching 100nM, which
included the physiological concentration at which reti-
noic acid is present in the human body.
Discussion
In the current study we were able to identify 868 inter-
actions between various chemical compounds and cyto-
chrome P450 regulators. We choose to follow the
interaction of retinoic acid on aromatase enzyme
because of its possible significant application towards
personalized medicine in endocrine therapy. The cell
lines chosen for this study are known to express
CYP19A1 and DAX1(HeLa). In the cell experiments, we
found that retinoic acid up-regulates the aromatase
enzyme. Retinoic acid a metabolite of Vitamin A is very
commonly found in various foods and dietary supple-
ments. Aromatase is a key enzyme involved in the
Figure 2 Compound - CYP Regulator - CYP Network. The above network shows the interaction between the Compounds, CYP regulators
and CYPs. Green arrows represent up regulation and red arrows represent down regulation of the respective gene. The interaction between
retinoic acid, DAX1 and CYP19A1 is highlighted by the yellow triangle.
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biosynthesis of estrogens [31,32], which can catalyze
the progression of estrogen-dependent breast cancers.
The levels of aromatase activity and mRNA expression are
higher in the breast cancer tissue than in normal tissue
[33-35]. In addition to the ovarian supply of estrogens,
aromatase enzyme is also involved in the local production
of estrogens through the conversion of circulating adrenal
androgens [36], thus having an immense potential to fuel
estrogen receptor positive breast cancer. DAX 1(dosage-
sensitive sex reversal adrenal hypoplasia congenital critical
region on the X-chromosome gene 1) is an orphan mem-
ber of the nuclear receptor family [37,38], and functions as
global anti-steroid factor and represses the expression of
many enzymes involved in the steroidogenic pathway,
including aromatase [39,40]. The expression of DAX 1 has
been reported in breast cancers [41,42], although it’s exact
mechanism is not fully understood. Aromatase inhibitors
were developed and widely utilized to treat endocrine
tumors [43], especially breast cancer with estrogen recep-
tor positive patients. Therefore, the up regulation of
aromatase would in turn result in higher levels of estro-
gens, and could possibly stimulate the endocrine tumor
growth. Most importantly, the usage of Vitamin A could
reduce the effectiveness of aromatase inhibitor treatment
for cancer. Given the fact that Vitamin A is so commonly
found in various food/supplement source, the chance for
its potential influence is higher, thus we chose to validate
its influence on aromatase expression.
Our initial bioinformatics finding using the MetaCore
database revealed that the presence of retinoic acid
caused an up regulation of DAX1 and which in turn
caused the down regulation of aromatase. In our func-
tional study, only one cell line, namely the HeLa cells
showed expression for DAX1. HeLa cells treated with
retinoic acid showed a down regulation of DAX1 and an
up regulation of aromatase expression. Though not in
the exact same direction as the bioinformatics prediction,
the overall experimental outcome in HeLa cells does
bring out the possibility that when present, DAX1
expression is inversely related to CYP19A1 expression in
the presence of retinoic acid. The other two cell lines did
not show any expression for DAX1 but did show that
retinoic acid up regulated CYP19A1 expression. DAX1 is
an orphan member of the nuclear receptor superfamily
of transcription factors, whose disruption has been linked
with increase expression of aromatase enzyme [39,44].
Even though the cell lines chosen for this study are from
extra gonadal sites it clearly shows that retinoic acid has
a significant influence on aromatase expression in the
presence or absence of DAX1. This finding is of impor-
tance as the use of aromatase inhibitors in treating breast
cancer is widespread [45,46]. Though aromatase inhibi-
tors are a gold standard in treating ER-positive breast
cancer, resistance to this therapy still requires the use of
other modes of suppression of intra-tumoral estrogen
production [36], thus calling for further investigation into
the underlying cause of resistance.
Conclusions
In this paper, we have shown that the use of curated
literature data is valuable in discovering novel drug
enzyme interactions, and potential clinically significant
Table 1. F-statistic along with the p-value for the effect
of ATRA on the expression of CYP19A1 (aromatase) and
DAX1 across the each cell lines
Cell Line Gene F(5/12) p-value
HeLa CYP19A1 9.7750 0.0007
DAX1 8.1982 0.0014
JEG3 CYP19A1 2.8328 0.0647
LNCaP CYP19A1 1.4003 0.2920
Figure 3 Relative fold change of Aromatase gene in response to various concentrations of ATRA.
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drug interactions. Our primary contribution is the estab-
lished feasibility of this translational bioinformatics
approach in detecting novel drug interaction signals.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LL and ZL guided the study. SP performed the bioinformatics and data
analysis, designed and carried out the wet lab experiments and wrote the
manuscript. TS provided the wet lab support. All authors read and approved
the final manuscript.
Acknowledgements
This project was supported by the following NIH grants R01GM10448301-A1
(LL), R01LM011945-01(LL) and R01GM088076(TS).
Declarations
Publication charges for this article have been funded by Dr. Lang Li.
This article has been published as part of BMC Genomics Volume 16
Supplement 7, 2015: Selected articles from The International Conference on
Intelligent Biology and Medicine (ICIBM) 2014: Genomics. The full contents
of the supplement are available online at http://www.biomedcentral.com/
bmcgenomics/supplements/16/S7.
Authors’ details
1School of Informatics and Computing, Indiana University-Purdue University
Indianapolis, 46202, USA. 2Harbin Medical University Cancer Hospital, Harbin,
Heilongjiang, 150040, China. 3Division of Clinical Pharmacology, Indiana
University School of Medicine, Indianapolis, 46202, USA. 4Center for
Computational Biology and Bioinformatics, Indiana University School of
Medicine, Indianapolis, 46202, USA.
Published: 11 June 2015
References
1. Ingelman-Sundberg M: The human genome project and novel aspects of
cytochrome P450 research. Toxicology and applied pharmacology 2005,
207(2 Suppl):52-56.
2. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ,
Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al: P450 superfamily:
update on new sequences, gene mapping, accession numbers and
nomenclature. Pharmacogenetics 1996, 6(1):1-42.
3. Bejjani BA, Lewis RA, Tomey KF, Anderson KL, Dueker DK, Jabak M,
Astle WF, Otterud B, Leppert M, Lupski JR: Mutations in CYP1B1, the gene
for cytochrome P4501B1, are the predominant cause of primary
congenital glaucoma in Saudi Arabia. American journal of human genetics
1998, 62(2):325-333.
4. Chavarria-Soley G, Sticht H, Aklillu E, Ingelman-Sundberg M, Pasutto F,
Reis A, Rautenstrauss B: Mutations in CYP1B1 cause primary congenital
glaucoma by reduction of either activity or abundance of the enzyme.
Human mutation 2008, 29(9):1147-1153.
5. Choudhary D, Jansson I, Schenkman JB: CYP1B1, a developmental gene
with a potential role in glaucoma therapy. Xenobiotica; the fate of foreign
compounds in biological systems 2009, 39(8):606-615.
6. Stoilov I, Akarsu AN, Sarfarazi M: Identification of three different
truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal
cause of primary congenital glaucoma (Buphthalmos) in families linked
to the GLC3A locus on chromosome 2p21. Human molecular genetics
1997, 6(4):641-647.
7. Vasiliou V, Gonzalez FJ: Role of CYP1B1 in glaucoma. Annual review of
pharmacology and toxicology 2008, 48:333-358.
8. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A,
Rivera CR, Mulvihill SJ, Malloy MJ, et al: Human cholesterol 7alpha-
hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
The Journal of clinical investigation 2002, 110(1):109-117.
9. Kobayashi K, Takahashi O, Hiratsuka M, Yamaotsu N, Hirono S, Watanabe Y,
Oda A: Evaluation of influence of single nucleotide polymorphisms in
cytochrome P450 2B6 on substrate recognition using computational
docking and molecular dynamics simulation. PloS one 2014, 16(5):e96789.
10. Drug Interactions. [http://medicine.iupui.edu/clinpharm/ddis/].
11. Ince I, Knibbe CA, Danhof M, de Wildt SN: Developmental changes in the
expression and function of cytochrome P450 3A isoforms: evidence
from in vitro and in vivo investigations. Clinical pharmacokinetics 2013,
52(5):333-345.
12. Soldin OP, Chung SH, Mattison DR: Sex differences in drug disposition.
Journal of biomedicine & biotechnology 2011, 2011:187103.
13. Zanger UM, Schwab M: Cytochrome P450 enzymes in drug metabolism:
regulation of gene expression, enzyme activities, and impact of genetic
variation. Pharmacology & therapeutics 2013, 138(1):103-141.
14. The Human Cytochrome P450 (CYP) Allele Nomenclature Database.
[http://www.cypalleles.ki.se/].
15. Cai Y, Konishi T, Han G, Campwala KH, French SW, Wan YJ: The role of
hepatocyte RXR alpha in xenobiotic-sensing nuclear receptor-mediated
pathways. European journal of pharmaceutical sciences : official journal of
the European Federation for Pharmaceutical Sciences 2002, 15(1):89-96.
16. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ,
Maurel P: Transcriptional regulation of CYP2C9 gene. Role of
glucocorticoid receptor and constitutive androstane receptor. The Journal
of biological chemistry 2002, 277(1):209-217.
17. Honkakoski P, Negishi M: Regulation of cytochrome P450 (CYP) genes by
nuclear receptors. The Biochemical journal 2000, 347(Pt 2):321-337.
18. Jover R, Moya M, Gomez-Lechon MJ: Transcriptional regulation of
cytochrome p450 genes by the nuclear receptor hepatocyte nuclear
factor 4-alpha. Current drug metabolism 2009, 10(5):508-519.
19. Li T, Chen W, Chiang JY: PXR induces CYP27A1 and regulates
cholesterol metabolism in the intestine. Journal of lipid research 2007,
48(2):373-384.
20. Lim YP, Huang JD: Interplay of pregnane × receptor with other nuclear
receptors on gene regulation. Drug metabolism and pharmacokinetics
2008, 23(1):14-21.
21. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ: Role of aryl hydrocarbon
receptor-mediated induction of the CYP1 enzymes in environmental
toxicity and cancer. The Journal of biological chemistry 2004,
279(23):23847-23850.
22. Plant N: The human cytochrome P450 sub-family: transcriptional
regulation, inter-individual variation and interaction networks. Biochimica
et biophysica acta 2007, 1770(3):478-488.
23. Wang D, Jiang Z, Shen Z, Wang H, Wang B, Shou W, Zheng H, Chu X, Shi J,
Huang W: Functional evaluation of genetic and environmental regulators
of p450 mRNA levels. PloS one 2011, 6(10):e24900.
24. Waxman DJ: P450 gene induction by structurally diverse xenochemicals:
central role of nuclear receptors CAR, PXR, and PPAR. Archives of
biochemistry and biophysics 1999, 369(1):11-23.
25. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM,
Sempos CT, Picciano MF: Dietary supplement use in the United States,
2003-2006. The Journal of nutrition 2011, 141(2):261-266.
26. Nekvindova J, Anzenbacher P: Interactions of food and dietary
supplements with drug metabolising cytochrome P450 enzymes. Ceska a
Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske
farmaceuticke spolecnosti 2007, 56(4):165-173.
Figure 4 Relative fold change of DAX1 gene in response to
various concentrations of ATRA.
Philips et al. BMC Genomics 2015, 16(Suppl 7):S17
http://www.biomedcentral.com/1471-2164/16/S7/s17
Page 6 of 7
27. Shetty KD, Dalal SR: Using information mining of the medical literature to
improve drug safety. Journal of the American Medical Informatics
Association : JAMIA 2011, 18(5):668-674.
28. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C,
Zhong H, Leeder JS, et al: Systematic genetic and genomic analysis of
cytochrome P450 enzyme activities in human liver. Genome research
2010, 20(8):1020-1036.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T: Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome
research 2003, 13(11):2498-2504.
30. Napoli JL: Quantification of physiological levels of retinoic acid. Methods
in enzymology 1986, 123:112-124.
31. Fishman J, Goto J: Mechanism of estrogen biosynthesis. Participation of
multiple enzyme sites in placental aromatase hydroxylations. The Journal
of biological chemistry 1981, 256(9):4466-4471.
32. Thompson EA, Siiteri PK: The involvement of human placental
microsomal cytochrome P-450 in aromatization. The Journal of biological
chemistry 1974, 249(17):5373-5378.
33. Miller WR: Aromatase activity in breast tissue. The Journal of steroid
biochemistry and molecular biology 1991, 39(5B):783-790.
34. Miller WR, Anderson TJ, Jack WJ: Relationship between tumour aromatase
activity, tumour characteristics and response to therapy. The Journal of
steroid biochemistry and molecular biology 1990, 37(6):1055-1059.
35. Utsumi T, Harada N, Maruta M, Takagi Y: Presence of alternatively spliced
transcripts of aromatase gene in human breast cancer. The Journal of
clinical endocrinology and metabolism 1996, 81(6):2344-2349.
36. Sasano H, Miki Y, Nagasaki S, Suzuki T: In situ estrogen production and its
regulation in human breast carcinoma: from endocrinology to
intracrinology. Pathology international 2009, 59(11):777-789.
37. Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, Tonini G, Ferrante E,
Chiumello G, McCabe ER, Fraccaro M, et al: A dosage sensitive locus at
chromosome Xp21 is involved in male to female sex reversal. Nature
genetics 1994, 7(4):497-501.
38. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E,
Moser C, Walker AP, McCabe ER, et al: An unusual member of the nuclear
hormone receptor superfamily responsible for X-linked adrenal
hypoplasia congenita. Nature 1994, 372(6507):635-641.
39. Wang ZJ, Jeffs B, Ito M, Achermann JC, Yu RN, Hales DB, Jameson JL:
Aromatase (Cyp19) expression is up-regulated by targeted disruption of
Dax1. Proceedings of the National Academy of Sciences of the United States
of America 2001, 98(14):7988-7993.
40. Zazopoulos E, Lalli E, Stocco DM, Sassone-Corsi P: DNA binding and
transcriptional repression by DAX-1 blocks steroidogenesis. Nature 1997,
390(6657):311-315.
41. Chae BJ, Lee A, Bae JS, Song BJ, Jung SS: Expression of nuclear receptor
DAX-1 and androgen receptor in human breast cancer. Journal of surgical
oncology 2011, 103(8):768-772.
42. Conde I, Alfaro JM, Fraile B, Ruiz A, Paniagua R, Arenas MI: DAX-1
expression in human breast cancer: comparison with estrogen receptors
ER-alpha, ER-beta and androgen receptor status. Breast cancer research :
BCR 2004, 6(3):R140-148.
43. Chen GG, Zeng Q, Tse GM: Estrogen and its receptors in cancer. Medicinal
research reviews 2008, 28(6):954-974.
44. Lanzino M, Maris P, Sirianni R, Barone I, Casaburi I, Chimento A, Giordano C,
Morelli C, Sisci D, Rizza P, et al: DAX-1, as an androgen-target gene,
inhibits aromatase expression: a novel mechanism blocking estrogen-
dependent breast cancer cell proliferation. Cell death & disease 2013, 4:
e724.
45. Miller WR: Aromatase inhibitors and breast cancer. Minerva
endocrinologica 2006, 31(1):27-46.
46. Puhalla S, Jankowitz RC, Davidson NE: Adjuvant endocrine therapy for
breast cancer: don’t ditch the switch! Journal of the National Cancer
Institute 2011, 103(17):1280-1282.
doi:10.1186/1471-2164-16-S7-S17
Cite this article as: Philips et al.: A translational bioinformatic approach
in identifying and validating an interaction between Vitamin A and
CYP19A1. BMC Genomics 2015 16(Suppl 7):S17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Philips et al. BMC Genomics 2015, 16(Suppl 7):S17
http://www.biomedcentral.com/1471-2164/16/S7/s17
Page 7 of 7
